Eli Lilly officials announced plans to release on the company's Web site "extensive" data on all phases of clinical trials conducted on most of Lilly's products, the Wall Street Journal reports. The move is an effort to "defuse criticism that pharmaceutical companies hush up negative results," according to the Journal. Under the new policy, once a drug receives FDA approval and reaches the market, Lilly will release all clinical trial data from early to late-stage phases. It will also release trial data from the past 10 years on all products currently available.

The Economist's  analysis of current demand for open access to research findings.

Google suffered an embarrassing glitch in its long-awaited £20 billion Wall Street flotation plans after the internet search engine company admitted breaching the rules of the Securities and Exchange Commission, the US regulator.

Google conceded that it had failed to disclose stock allocations worth $3.1 billion (£1.7 billion) at flotation to staff and consultants over the past three years.

The Barclay brothers are not expected to face a “public interest” regulatory test over their take-over of The Daily Telegraph, according to officials who would be responsible for leading such an inquiry. Senior executives of Ofcom, the communication regulator, claim in private that they do not expect to be asked by Patricia Hewitt, Trade and Industry Secretary, to intervene in the £665 million take-over.